**Supplementary Table 2. Clinical parameters associated with significant fibrosis in the training group (290 patients).**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | | | **No significant fibrosis**  **(*n=*201)** | **significant fibrosis**  **(*n=*89)** | ***p*-value** |
| Age (years) | | | 37.72±10.51 | 37.47±11.21 | 0.855 |
| Sex | Male | | 124 (61.7%) | 60 (67.4%) | 0.212 |
| Female | | 77 (38.3%) | 29 (32.6%) |
| Total bilirubin (μmol/L) | | | 14.96±7.82 | 15.18±9.50 | 0.842 |
| Albumin (g/L) | | | 43.26±4.09 | 39.38±6.24 | <0.001 |
| Globulin (g/L) | | | 25.14±8.29 | 23.66±10.67 | 0.432 |
| ALT (U/L) | | | 25.11±7.81 | 26.92±7.63 | 0.068 |
| AST (U/L) | | | 22.30±5.77 | 24.69±6.73 | 0.02 |
| GGT (U/L) | | | 18.84±10.39 | 32.51±17.36 | <0.001 |
| TCHO (mmol/L) | | | 4.49±0.80 | 4.70±1.66 | 0.455 |
| CHE (Log U/L) | | 3.90±0.11 | | 3.87±0.10 | 0.03 |
| WBC (109/L) | | 5.77±1.45 | | 5.92±1.49 | 0.431 |
| PLT (109/L) | | 220.06±53.90 | | 184.92±53.19 | <0.001 |
| HBsAg (Log IU/mL) | | 3.54±1.04 | | 3.06±0.72 | <0.001 |
| HBV DNA (Log IU/mL) | | 5.68±2.03 | | 4.93±1.81 | 0.010 |
| PT (s) | | 12.65±1.00 | | 12.54±1.10 | 0.392 |
| INR | | 1.00±0.07 | | 1.05±0.08 | 0.013 |

Data are *n* (%) or mean±SEM. ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma glutamyl transpeptidase; TCHO, total cholesterol; CHE, cholinesterase; WBC, white blood cell count; PLT, platelet count; HBV, hepatitis B virus; PT, prothrombin time; INR, international normalized ratio.